• Sophia Genetics posted Q2 revenue of USD 23.3 million, up 27% year over year; net loss was USD 22.4 million, flat year over year.
• Gross margin fell 2.4 percentage points to 64.6% on a reported basis; adjusted gross margin slipped 2.3 points to 72.1% on a non-IFRS basis.
• Adjusted EBITDA loss narrowed 27% to USD 8.8 million on a non-IFRS basis; cash and cash equivalents rose to USD 107.7 million after a USD 57.5 million offering.
• Net dollar retention increased to 117% from 107% a year earlier; analyses on SOPHiA DDM climbed 22% to 115,000.
• Raised 2026 revenue guidance to USD 94 million-USD 96 million from USD 92 million-USD 94 million; expects adjusted EBITDA loss of USD 29 million-USD 32 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608040645PR_NEWS_USPR_____NE18232) on August 04, 2026, and is solely responsible for the information contained therein.